Roche mtm laboratories AG; Bringing the Power of p16 to the prevention of cervical cancer

Worldwide, cervical cancer is the second most common cancer in women, with over 400,000 cases per year. Identifying High-grade disease early, the immediate pre-cursor to cancer, is a critical component to a good prognosis.    

mtm’s patent protected CINtec® products are adjunctive tools for histology and cytology, applications that enable the early and accurate detection of cervical disease. CINtec® products are based on detecting the over-expression of the cellular protein p16INK4a (p16), a biomarker correlated with the oncogenic transformation of cervical cells’ response to persistent infection with High Risk Human Papilloma Virus (HR-HPV). Identifying the over-expression of p16 offers the potential for highly specific and accurate diagnosis of even symptomless early stages of cervical disease. mtm is currently marketing CINtec® Histology and CINtec® PLUS Cytology as adjunctive tools for the early detection of cervical cancer .

mtm is ISO 9001 and 13485 certified and operates on a global basis with headquarters in Heidelberg, Germany, and subsidiaries in the United States, France, Italy, Spain and Japan.